Keywords: Bristol-Myers Squibb, Amira Pharma, Fibrotic diseases, M&A
Bristol-Myers Squibb to pay up to $475 million to acquire Amira, entering fibrotic disease area
Article | 22 July 2011
US drug major Bristol-Myers Squibb (NYSE: BMY) has signed a definitive agreement to acquire privately held Amira Pharmaceuticals, a small-molecule ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
